Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-574
Specific or universal ncRNAs
Specific ncRNAs
Class
MicroRNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
SMAD4
Cancer name
Breast Cancer
Cancer site
Breast
Treatment type
Chemotherapy
Drug
Doxorubicin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
We revealed miR-574 could promote doxorubicin resistance of breast cancer MCF-7 cells via down-regulating SMAD4, thus providing a novel target for advancing breast cancer chemotherapy.
Tissue resource
blood samples of breast cancer patients
breast cancer cell lines MCF-7
breast cancer adriamycin-resistant cell lines MCF-7/ADR
Experiment
qRT-PCR,Western blot,Dual-luciferase reporter assay
Institute
Yantai Yuhuangding Hospital
KeyGENE
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.